皮肤T细胞淋巴瘤的局部和全身制剂选择
Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.
作者信息
Fujimura Taku, Amagai Ryo, Kambayashi Yumi, Aiba Setsuya
机构信息
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
出版信息
Pharmaceutics. 2021 Feb 2;13(2):200. doi: 10.3390/pharmaceutics13020200.
Abstract
Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.
摘要
尽管有多种抗皮肤T细胞淋巴瘤（CTCL）疗法可供临床使用，但用于治疗CTCL的合适化疗方案尚未确立。因此，迄今为止，针对晚期CTCL治疗的各种临床试验正在进行中。在本综述中，我们评估了临床实践中可用于治疗早期和晚期CTCL的治疗选择（靶向疗法、组蛋白去乙酰化酶（HDAC）抑制剂、维甲酸、干扰素、细胞毒性药物等）。我们还研究了治疗CTCL的新型方案的临床试验。
相似文献
1
Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.皮肤T细胞淋巴瘤的局部和全身制剂选择
Pharmaceutics. 2021 Feb 2;13(2):200. doi: 10.3390/pharmaceutics13020200.
2
Management of refractory early-stage cutaneous T-cell lymphoma.难治性早期皮肤T细胞淋巴瘤的管理
Am J Clin Dermatol. 2006;7(3):155-69. doi: 10.2165/00128071-200607030-00002.
3
Treatment of cutaneous T cell lymphoma: current status and future directions.皮肤T细胞淋巴瘤的治疗：现状与未来方向
Am J Clin Dermatol. 2002;3(3):193-215. doi: 10.2165/00128071-200203030-00006.
4
DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors .DOT1L抑制不会改变皮肤T细胞淋巴瘤对泛组蛋白去乙酰化酶抑制剂的敏感性。
Front Genet. 2022 Nov 8;13:1032958. doi: 10.3389/fgene.2022.1032958. eCollection 2022.
5
Systemic therapy of cutaneous T-cell lymphoma (CTCL).皮肤T细胞淋巴瘤（CTCL）的全身治疗。
Chin Clin Oncol. 2019 Feb;8(1):10. doi: 10.21037/cco.2019.01.02.
6
Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.倍他罗汀在治疗皮肤 T 细胞淋巴瘤中的作用：临床和免疫学方面。
Immunotherapy. 2013 Apr;5(4):427-33. doi: 10.2217/imt.13.15.
7
The optimal use of bexarotene in cutaneous T-cell lymphoma.贝沙罗汀在皮肤T细胞淋巴瘤中的最佳应用。
Br J Dermatol. 2007 Sep;157(3):433-40. doi: 10.1111/j.1365-2133.2007.07975.x. Epub 2007 Jun 6.
8
Novel therapies for cutaneous T-cell lymphomas.皮肤T细胞淋巴瘤的新型疗法。
Clin Lymphoma Myeloma. 2008 Dec;8 Suppl 5:S187-92. doi: 10.3816/CLM.2008.s.015.
9
Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.皮肤 T 细胞淋巴瘤中组蛋白去乙酰化酶抑制剂的现状。
Am J Clin Dermatol. 2018 Dec;19(6):805-819. doi: 10.1007/s40257-018-0380-7.
10
Treatment of cutaneous T-cell lymphoma with retinoids.用维甲酸治疗皮肤T细胞淋巴瘤。
Dermatol Ther. 2006 Sep-Oct;19(5):264-71. doi: 10.1111/j.1529-8019.2006.00083.x.
引用本文的文献
1
Successful Treatment of Poikilodermatous Mycosis Fungoides with 308-nm Excimer Laser.308纳米准分子激光成功治疗斑驳样蕈样肉芽肿
Case Rep Oncol. 2025 Feb 12;18(1):325-329. doi: 10.1159/000544164. eCollection 2025 Jan-Dec.
2
A Super-Aged Patient with Primary Cutaneous Gamma-Delta T-Cell Lymphoma Treated with Palliative Radiotherapy: A Short-Term Follow-Up Case.一名接受姑息性放疗的原发性皮肤γ-δ T细胞淋巴瘤超老龄患者：短期随访病例
Case Rep Oncol. 2025 Jun 7;18(1):905-911. doi: 10.1159/000546761. eCollection 2025 Jan-Dec.
3
Impact of Hyaluronic Acid on the Cutaneous T-Cell Lymphoma Microenvironment: A Novel Anti-Tumor Mechanism of Bexarotene.透明质酸对皮肤T细胞淋巴瘤微环境的影响：贝沙罗汀的一种新型抗肿瘤机制。
Cancers (Basel). 2025 Jan 20;17(2):324. doi: 10.3390/cancers17020324.
4
A Retrospective Cohort Study to Determine Real-World Treatment Patterns in Patients with Sézary Syndrome in the United States.一项回顾性队列研究，以确定美国蕈样肉芽肿综合征患者的真实世界治疗模式。
Oncol Ther. 2024 Dec;12(4):775-786. doi: 10.1007/s40487-024-00306-2. Epub 2024 Sep 21.
5
CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T-cell lymphomas.CD25表达可能是贝沙罗汀单药治疗皮肤T细胞淋巴瘤的一个预后标志物。
Skin Health Dis. 2023 Feb 12;3(3):e222. doi: 10.1002/ski2.222. eCollection 2023 Jun.
6
Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox.地尼白介素妥昔单抗成功治疗原发性皮肤间变性大细胞淋巴瘤
Case Rep Oncol. 2022 Aug 26;15(2):726-731. doi: 10.1159/000526312. eCollection 2022 May-Aug.
7
Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers.基质因子作为黑色素瘤和非黑色素瘤皮肤癌免疫治疗的靶点
Int J Mol Sci. 2022 Apr 6;23(7):4044. doi: 10.3390/ijms23074044.
8
Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene.白细胞中免疫反应性细胞的定量分析有助于诊断贝沙罗汀引起的药疹。
Case Rep Oncol. 2022 Feb 1;15(1):40-45. doi: 10.1159/000521843. eCollection 2022 Jan-Apr.
本文引用的文献
1
Tumors establish resistance to immunotherapy by regulating T recruitment via CCR4.肿瘤通过调节 T 细胞募集来建立对免疫疗法的抵抗，这是通过 CCR4 实现的。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-000764.
2
Treatment of Advanced Melanoma: Past, Present and Future.晚期黑色素瘤的治疗：过去、现在与未来
Life (Basel). 2020 Sep 16;10(9):208. doi: 10.3390/life10090208.
3
Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab.同步使用放射治疗、龙胆紫和莫加莫单抗诱导一名晚期皮肤T细胞淋巴瘤患者缓解
JAAD Case Rep. 2020 Jun 4;6(8):761-765. doi: 10.1016/j.jdcr.2020.05.035. eCollection 2020 Aug.
4
Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.在用莫加莫珠单抗治疗的CCR4阳性蕈样肉芽肿中，血清CCL22水平随疾病活动度平行下降。
Dermatol Ther. 2020 Nov;33(6):e14099. doi: 10.1111/dth.14099. Epub 2020 Aug 17.
5
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.NCCN 指南解读：原发性皮肤淋巴瘤，第 2.2020 版。
J Natl Compr Canc Netw. 2020 May;18(5):522-536. doi: 10.6004/jnccn.2020.0022.
6
Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment.用莫加莫拉单抗联合依托泊苷治疗对莫加莫拉单抗耐药的蕈样肉芽肿：依托泊苷对肿瘤微环境免疫调节作用的研究
Dermatol Ther. 2020 Jul;33(4):e13487. doi: 10.1111/dth.13487. Epub 2020 May 22.
7
Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.采用贝沙罗汀为基础的疗法治疗皮肤 T 细胞淋巴瘤的病例系列研究。
J Dermatol. 2020 Jun;47(6):636-640. doi: 10.1111/1346-8138.15322. Epub 2020 Mar 24.
8
Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.贝沙罗汀联合光（化）疗治疗皮肤 T 细胞淋巴瘤的疗效和安全性。
J Dermatol. 2020 May;47(5):443-451. doi: 10.1111/1346-8138.15310. Epub 2020 Mar 18.
9
Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.氮芥凝胶治疗蕈样肉芽肿型皮肤淋巴瘤患者的真实世界经验：一项前瞻性观察研究的初步结果
J Am Acad Dermatol. 2020 Sep;83(3):928-930. doi: 10.1016/j.jaad.2019.12.070. Epub 2020 Feb 20.
10
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.本妥昔单抗维特金治疗外周 T 细胞淋巴瘤和皮肤 T 细胞淋巴瘤。
Curr Hematol Malig Rep. 2020 Feb;15(1):9-19. doi: 10.1007/s11899-020-00561-w.
Zotero 插件